(Q44687349)

5 December 2017

Early benefit from structured care with atorvastatin in patients with coronary heart disease and diabetes mellitus (English)

1 reference

5 December 2017

1 reference

coronary artery disease

1 reference

Vasilios G Athyros

1

1 reference

5 December 2017

Athanasios A Papageorgiou

2

1 reference

5 December 2017

Athanasios N Symeonidis

3

1 reference

5 December 2017

Triandafillos P Didangelos

4

1 reference

5 December 2017

Anthimos N Pehlivanidis

5

1 reference

5 December 2017

Vasilios I Bouloukos

6

1 reference

5 December 2017

Dimitrios P Mikhailidis

7

1 reference

5 December 2017

GREACE Study Collaborative Group

8

1 reference

5 December 2017

1 November 2003

1 reference

5 December 2017

1 reference

5 December 2017

54

1 reference

5 December 2017

6

1 reference

5 December 2017

679-690

1 reference

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

5 December 2017

1 reference

https://api.crossref.org/works/10.1177%2F000331970305400607

Cardiovascular risk factor profile in Greece: results from the CARDIO2000 and ATTICA epidemiological studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000331970305400607

Treatment with atorvastatin to the National Cholesterol Educational Program goal versus 'usual' care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000331970305400607

Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000331970305400607

Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000331970305400607

The aggressive low density lipoprotein lowering controversy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000331970305400607

Clustering of cardiovascular risk factors: targeting high-risk individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000331970305400607

Correlation of non-high-density lipoprotein cholesterol with apolipoprotein B: effect of 5 hydroxymethylglutaryl coenzyme A reductase inhibitors on non-high-density lipoprotein cholesterol levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000331970305400607

Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000331970305400607

The diet and 15-year death rate in the seven countries study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000331970305400607

Lipid-lowering medication for secondary prevention of coronary heart disease in a German outpatient population: the gap between treatment guidelines and real life treatment patterns

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000331970305400607

Use of lipid-lowering medications at discharge in patients with acute myocardial infarction: data from the National Registry of Myocardial Infarction 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000331970305400607

Cardiovascular risk management in clinical practice: the Midwest Heart Specialists experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000331970305400607

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000331970305400607

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000331970305400607

Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000331970305400607

Design of the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000331970305400607

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre ra

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000331970305400607

American Heart Association Prevention Conference. IV. Prevention and Rehabilitation of Stroke. Risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000331970305400607

Pravastatin Therapy and the Risk of Stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000331970305400607

Stroke, statins, and cholesterol. A meta-analysis of randomized, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000331970305400607

The early effect of lipid-lowering treatment on carotid and femoral intima media thickness (IMT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000331970305400607

Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000331970305400607

MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000331970305400607

Statins and renal function in patients with diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000331970305400607

Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000331970305400607

Statins and renal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000331970305400607

Early vascular benefits of statin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000331970305400607

Predictors of subsequent coronary events, stroke, and death among survivors of first hospitalized myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000331970305400607

Pharmacoeconomics of lipid-lowering agents for primary and secondary prevention of coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000331970305400607

The cost-effectiveness of lipid lowering in patients with diabetes: results from the 4S trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000331970305400607

Effect of simvastatin treatment on cardiovascular resource utilization in impaired fasting glucose and diabetes. Findings from the Scandinavian Simvastatin Survival Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000331970305400607

The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000331970305400607

Attaining United Kingdom-European Atherosclerosis Society low-density lipoprotein cholesterol guideline target values in the Greek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F000331970305400607

10.1177/000331970305400607

21 January 2018

Identifiers

DOI

1 reference

5 December 2017

1 reference